/STX.L
STX.L Stock - Shield Therapeutics plc
Healthcare|Drug Manufacturers - Specialty & GenericLSE
$11.00-2.22%
$0.25 (-2.22%) • Dec 22
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $12.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.89 – $11.11
TARGET (TP)$12.65
STOP LOSS$10.12
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.76
52W High$12.50
52W Low$2.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $25.18M | $13.09M | $5.50M | $1.52M | $10.39M |
| Gross Profit | $10.57M | $4.03M | $2.00M | $539,000 | $9.03M |
| Gross Margin | 42.0% | 30.8% | 36.3% | 35.5% | 87.0% |
| Operating Income | $-17,976,035 | $-31,331,000 | $-26,391,072 | $-20,405,000 | $-2,154,000 |
| Net Income | $-21,272,294 | $-33,293,000 | $-40,444,000 | $-19,336,000 | $-2,630,000 |
| Net Margin | -84.5% | -254.4% | -735.5% | -1272.9% | -25.3% |
| EPS | $-0.02 | $-0.04 | $-0.17 | $-0.09 | $-0.02 |
Company Overview
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
STX.LBeat Rate
100%
Last 1 quarters
Avg Surprise
+17.1%
EPS vs Estimate
Beats / Misses
1/0
Last 12 quarters
Latest EPS
$-0.01
Q2 2025
EPS Surprise History
Q4 22
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
+17.1%
$-0.01vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q2 2025 | Apr 24, 2025 | $-0.01 | $-0.01 | +17.1% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 4, 2024 | — | $-0.02 | — | — |
Q2 2024 | Jun 29, 2024 | — | $-0.02 | — | — |
Q2 2024 | Apr 30, 2024 | — | — | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.02 | — | — |
Q3 2023 | Sep 28, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 28, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 27, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.11 | — | — |
Q3 2022 | Sep 8, 2022 | — | $-0.05 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.05 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.04 | — | — |
Q2 2021 | Apr 29, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q3 2020 | Sep 16, 2020 | — | $0.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Latest News
Loading news...
Frequently Asked Questions about STX.L
What is STX.L's current stock price?
Shield Therapeutics plc (STX.L) is currently trading at $11.00 per share. The stock has moved -2.22% today.
What is the analyst price target for STX.L?
No analyst price targets are currently available for this stock.
What sector is Shield Therapeutics plc in?
Shield Therapeutics plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the LSE exchange.
What is STX.L's market cap?
Shield Therapeutics plc has a market capitalization of $0.12 billion, making it a small-cap company.
Does STX.L pay dividends?
No, Shield Therapeutics plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBVC.L
BATM Advanced Communications Ltd.
$16.48
Mkt Cap: $7.2B
CHLL.L
Chill Brands Group PLC
$0.78
Mkt Cap: $0.4B
CREO.L
Creo Medical Limited
$10.15
Mkt Cap: $4.2B
EAH.L
ECO Animal Health Group plc
$103.50
Mkt Cap: $7.0B
HEMO.L
Hemogenyx Pharmaceuticals Plc
$634.00
Mkt Cap: $3.8B
IMM.L
ImmuPharma plc
$5.30
Mkt Cap: $2.7B
OBI.L
Ondine Biomedical Inc.
$9.00
Mkt Cap: $3.9B
SCLP.L
Scancell Holdings plc
$9.90
Mkt Cap: $10.3B
SPEC.L
INSPECS Group plc
$71.00
Mkt Cap: $7.2B
VLG.L
Venture Life Group plc
$66.00
Mkt Cap: $8.4B
Explore stocks similar to STX.L for comparison